^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CLN-978

    i
    Other names: CLN-978
    Company:
    Cullinan Therap
    Drug class:
    CD3 agonist, CD19 inhibitor
    Related drugs:
    1m
    CLN-978-RA-101: A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA) (2024-519114-31-00)
    P1, N=46, Recruiting, Cullinan Therapeutics Inc.
    New P1 trial
    |
    CLN-978
    1m
    CLN-978-RA-101: A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA) (2024-519114-31-00)
    P1, N=46, Recruiting, Cullinan Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLN-978
    1m
    CLN-978-SL-101: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=24, Recruiting, Cullinan Therapeutics Inc. | N=44 --> 24
    Enrollment change
    |
    CLN-978
    2ms
    CLN-978-SJ-101: A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogrens Disease (2025-521462-96-00)
    P1, N=40, Recruiting, Cullinan Therapeutics Inc. | N=30 --> 40
    Enrollment change
    |
    CLN-978
    2ms
    CLN-978-SL-101: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=34, Recruiting, Cullinan Therapeutics Inc. | N=24 --> 34
    Enrollment change
    |
    CLN-978
    3ms
    CLN-978-SJ-101: A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogrens Disease (2025-521462-96-00)
    P1, N=30, Recruiting, Cullinan Therapeutics Inc.
    New P1 trial
    |
    CLN-978
    4ms
    CLN-978-SL-101: A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE) (2024-518780-36-00)
    P1, N=8, Recruiting, Cullinan Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLN-978
    4ms
    CLN-978-SL-101: A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE) (2024-518780-36-00)
    P1, N=8, Not yet recruiting, Cullinan Therapeutics Inc.
    New P1 trial
    |
    CLN-978
    12ms
    A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease (clinicaltrials.gov)
    P1, N=36, Recruiting, Cullinan Therapeutics Inc.
    New P1 trial
    |
    CLN-978
    1year
    A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=37, Recruiting, Cullinan Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLN-978
    1year
    A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=37, Not yet recruiting, Cullinan Therapeutics Inc.
    New P1 trial
    |
    CLN-978
    over1year
    A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=24, Recruiting, Cullinan Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLN-978